nach oben

Current Atherosclerosis Reports

Erschienen in:

01.12.2021 | Reviews and New Research Implications (S. Virani, Section Editor)

Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress

verfasst von: Michelle T. Lee, Dhruv Mahtta, Louis Dlouhy, Hunaina Shahab, Mahmoud Al Rifai, Salim S. Virani

Erschienen in: Current Atherosclerosis Reports | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review highlights select studies presented at the virtual 2021 European Society of Cardiology (ESC) Congress.

Recent Findings

Reviewed studies assess single photon emission computed tomography, positron emission tomography, magnetic resonance imaging in coronary artery disease (PACIFIC-II); empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); dapagliflozin in chronic heart failure (DAPA-HF); proprotein convertase subtilisin/kexin type 9 inhibitor and its lipid lowering effects (NATURE-PCSK9); fixed-dose combination therapies with or without aspirin in primary prevention; overview of contrasting results between REDUCE-IT versus STRENGTH trials; Quadruple UltrA-low-dose tReaTment for hypertension (QUARTET); evolocumab and changes in plaque composition on optical coherence tomography (HUYGENS); and low-dose rivaroxaban during the acute phase of acute coronary syndrome (H-REPLACE).

Summary

Research presented at the 2021 ESC Congress shows promise in reducing burden of cardiovascular disease and reinforces the value of cardiovascular disease prevention.

1.••

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2107038. In a randomized trial of 5988 heart failure patients with left ventricular ejection fraction >40%, empagliflozin (compared with placebo) was associated with a significant risk reduction in the composite end point of cardiovascular death and first hospitalization for heart failure.

2.••

Curtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Køber L, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021;42(36):3727–38. https://doi.org/10.1093/eurheartj/ehab560. In a randomized trial of 4,744 heart failure patients with reduced left ventricular ejection fraction, dapagliflozin (compared with placebo) was associated with a significant risk reduction in the composite end point of ventricular arrhythmias and sudden death.

Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: An individual participant data meta-analysis. Lancet. 2021;398(10306):1133–46. https://doi.org/10.1016/S0140-6736(21)01827-4.CrossRefPubMed

Doi T, Langsted A, Nordestgaard BG. A possible explanation for the contrasting results of reduce-it vs. Strength: Cohort study mimicking trial designs. Eur Heart J. 2021. https://doi.org/10.1093/eurheartj/ehab555.

5.•

Nicholls SJ, Nissen SE, Prati F, et al. Assessing the impact of pcsk9 inhibition on coronary plaque phenotype with optical coherence tomography: Rationale and design of the randomized, placebo-controlled huygens study. Cardiovasc Diagn Ther. 2021;11(1):120–9 This international double-blind, placebo-controlled randomized controlled trial of 161 patients demonstrated that adding evolucomab to statin therapy among patients after an acute coronary syndrome resulted in a greater increase in minimum fibrous cap thickness and decrease in maximum lipid arc.CrossRef

Jain V, Al Rifai M, Mahtta D, Liu J, Hussain A, Virani SS. Highlights from studies presented at the virtual american college of cardiology scientific sessions 2021: Staying updated with the latest advancements in prevention. Curr Atheroscler Rep. 2021;23(9):50.CrossRef

Hussain A, Al Rifai M, Mahtta D, Liu J, Jain V, Virani SS. Highlights from studies presented at the american heart association scientific session 2020: Navigating new roads in prevention. Curr Atheroscler Rep. 2021;23(1):4.CrossRef

Al Rifai M, Jia X, Al-Mallah MH, Miedema MD, Martin SS, Virani SS. Major randomized clinical trials in cardiovascular disease prevention presented at the 2019 american college of cardiology annual scientific session. Curr Atheroscler Rep. 2019;21(8):31.CrossRef

Jia X, Al Rifai M, Gluckman TJ, Birnbaum Y, Virani SS. Highlights from selected cardiovascular disease prevention studies presented at the 2019 european society of cardiology congress. Curr Atheroscler Rep. 2019;21(12):46.CrossRef

10.

Knuuti J, Wijns W, Saraste A, et al. 2019 esc guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77.CrossRef

11.

Jones T, Townsend D. History and future technical innovation in positron emission tomography. J Med Imaging (Bellingham). 2017;4(1):011013.CrossRef

12.

Devine CE, Mawlawi O. Radiation safety with positron emission tomography and computed tomography. Semin Ultrasound CT MR. 2010;31(1):39–45.CrossRef

13.

Desiderio MC, Lundbye JB, Baker WL, Farrell MB, Jerome SD, Heller GV. Current status of patient radiation exposure of cardiac positron emission tomography and single-photon emission computed tomographic myocardial perfusion imaging. Circ Cardiovasc Imaging. 2018;11(12):e007565.CrossRef

14.

Mcmurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.CrossRef

15.•

Yusuf S, Joseph P, Dans A, et al. Polypill with or without aspirin in persons without cardiovascular disease. N Engl J Med. 2021;384(3):216–28 This meta-analysis of large randomized controlled trials assessed a fixed-dose combination strategy approach of at least 2 BP lowering agents and statin (with or without aspirin) versus a control (placebo or usual care) in a primary cardiovascular disease prevention patient population.CrossRef

16.

Miedema MD, Huguelet J, Virani SS. Aspirin for the primary prevention of cardiovascular disease: In need of clarity. Curr Atheroscler Rep. 2016;18(1):4.CrossRef

17.

Miedema MD, Virani SS. Aspirin reduces cardiovascular events in primary prevention of cardiovascular disease but at a near equivalent risk of increased bleeding. Evid Based Med. 2016;21(6):225.CrossRef

18.

Arnett DK, Blumenthal RS, Albert MA, et al. 2019 acc/aha guideline on the primary prevention of cardiovascular disease: Executive summary: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation. 2019;140(11):e563–95.PubMedPubMedCentral

19.

Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306–13.CrossRef

20.

Mcneil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379(16):1509–18.CrossRef

21.

Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22.CrossRef

22.

Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: The strength randomized clinical trial. JAMA. 2020;324(22):2268–80.CrossRef

23.

Virani SS, Nambi V, Ballantyne CM. Has the ‘strength’ of fish oil therapy been ‘reduced’? Reconciling the results of reduce-it and strength. Eur Heart J Cardiovasc Pharmacother. 2021;7(3):e7-8.CrossRef

24.

Chow CK, Gupta R. Blood pressure control: A challenge to global health systems. Lancet. 2019;394(10199):613–5.CrossRef

25.

Chow CK, Thakkar J, Bennett A, et al. Quarter-dose quadruple combination therapy for initial treatment of hypertension: Placebo-controlled, crossover, randomised trial and systematic review. Lancet. 2017;389(10073):1035–42.CrossRef

26.

Prati F, Romagnoli E, Gatto L, et al. Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: The clima study. Eur Heart J. 2020;41(3):383–91.PubMed

27.

Kataoka Y, Puri R, Hammadah M, et al. Frequency-domain optical coherence tomographic analysis of plaque microstructures at nonculprit narrowings in patients receiving potent statin therapy. Am J Cardiol. 2014;114(4):549–54.CrossRef

28.

Zou Z, Cini K, Dong B, et al. Time trends in cardiovascular disease mortality across the brics: An age-period-cohort analysis of key nations with emerging economies using the global burden of disease study 2017. Circulation. 2020;141(10):790–9.CrossRef

29.

Huo Y. Current status and development of percutaneous coronary intervention in china. J Zhejiang Univ Sci B. 2010;11(8):631–3.CrossRef

30.

Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19.CrossRef

31.

Ohman EM, Roe MT, Steg PG, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to p2y12 inhibition, in acute coronary syndromes (gemini-acs-1): A double-blind, multicentre, randomised trial. Lancet. 2017;389(10081):1799–808.CrossRef

Titel: Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress
verfasst von: Michelle T. Lee
Dhruv Mahtta
Louis Dlouhy
Hunaina Shahab
Mahmoud Al Rifai
Salim S. Virani
Publikationsdatum: 01.12.2021
Verlag: Springer US
Erschienen in: Current Atherosclerosis Reports / Ausgabe 12/2021
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-021-00975-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress